

**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. **(withdrawn):** A method for treatment of neuropsychiatric disorders which comprises administration of a D-serine transport inhibitor at a dose sufficient to enhance NMDA receptor-mediated neurotransmission in vivo.
2. **(withdrawn):** The method of claim 1 wherein the disorder is associated with decreased *N*-methyl-D-aspartate (NMDA) receptor-mediated neurotransmission.
3. **(withdrawn):** The method of claim 1 wherein the disorder is a psychotic disorder.
4. **(withdrawn):** The method of claim 3 wherein the psychotic disorder is schizophrenia.
5. **(withdrawn):** The method of claim 1 wherein the disorder is Alzheimer's disease, bipolar illness, depression and anxiety disorders, stroke or epilepsy.
6. **(withdrawn):** The method of claim 1 wherein the disorder is age associated memory impairment, closed head injury or attention deficit disorder.

7.     **(withdrawn):** The method of claim 1 wherein such agent is administered orally.
8.     **(withdrawn):** The method of claim 1 wherein a D-serine transport inhibitor is administered parenterally.
9.     **(withdrawn):** A method for augmentation of *N-methyl-D*-aspartate receptor-mediated neurotransmission in vivo which comprises administration of a D-serine transport antagonist.
10.    **(withdrawn):** The method of claim 1 or 9 wherein the antagonist is an inhibitor of D-serine transport mediated through system ASC.
11.    **(withdrawn):** The method of claim 1 or 9 wherein the antagonist is an inhibitor of systems L, N, A or Gly.
12.    **(withdrawn):** The method of claim 1 or 9 wherein the antagonist is an inhibitor of alanine-sensitive D-serine transport.
13.    **(withdrawn):** The method of claim 1 or 9 where the antagonist is an inhibitor of alanine-insensitive D-serine transport.

14. **(withdrawn):** The method of claim 1 or 9 wherein the agent is glycyldodecylamide, D-serine dodecylamide (d-ser-da) or D-alanine dodecylamide.
15. **(withdrawn):** The method of claim 1 or 9 wherein the agent is used in combination with typical or atypical antipsychotics administered orally, parenterally or by depot formulation.
16. **(withdrawn):** The method of claim 1 or 9 wherein the agent is used in combination with other treatments commonly used in schizophrenia, including but not limited to antidepressants, mood stabilizers, or antianxiety agents.
17. **(withdrawn):** The method of claim 1 or 9 wherein the agent is used in combination with a glycine transport inhibitor.
18. **(currently amended):** A composition for treating schizophrenia comprising an effective amount of a selective D-serine transport inhibitor comprising a serine or alanine compound having a hydrophobic group selected from the group consisting of a ~~C1-C13 alkyl group, a phenyl group,~~ a C1-C13 phenylalkyl group, a cyano group, a ~~halogen group~~ and a C1-C13 haloalkyl group, which is linked to at least one of the C- and N-terminus of the serine or alanine compound as the active ingredient and a pharmaceutically acceptable carrier.

19. **(currently amended):** ~~The composition of claim 18, wherein the D-serine transport inhibitor is~~ A composition for treating schizophrenia comprising an effective amount of a selective D-serine transport inhibitor compound as the active ingredient and a pharmaceutically acceptable carrier, wherein the D-serine transport inhibitor compound is D-alanine dodecylamide.

20. **(canceled).**

21. **(previously presented):** The composition of claim 18, wherein the D-serine transport inhibitor is present in an amount sufficient to augment NMDA-mediated neurotransmission and is combined with a typical or atypical antipsychotic agent administerable orally or parenterally.

22. **(canceled).**

23. **(canceled).**

24. **(canceled).**

25. **(withdrawn):** A method of claim 1 wherein a composition of claim 20 is used.

**26. (withdrawn):** A method of claim 9 wherein a composition of claim 20 is used.

**27-44 (canceled).**

**45. (canceled).**

**46. (new):** The composition of claim 19, wherein the D-serine transport inhibitor is present in an amount sufficient to augment NMDA-mediated neurotransmission and is combined with a typical or atypical antipsychotic agent administerable orally or parenterally.